GLP-1 Studio
GLP-1 Studio Daily
What happened after two men quit tirzepatide?
0:00
-3:18

What happened after two men quit tirzepatide?

Plus a brain aging trial, 200 drugs in development and a Boots case
A psychologist and a patient talking during a therapy session indoors.
Photo by Vitaly Gariev on Pexels

Good morning! Two men developed mood and psychotic symptoms after they stopped taking tirzepatide. Also today: a brain aging trial in 180 generally healthy adults, more than 200 GLP-1 drugs in development, and a Boots worker sentenced over Mounjaro. Listen to me read them above, or read the key details below.

Daily Roundup:

  1. Two men developed mood and psychotic symptoms after they stopped taking tirzepatide (Primary Care Companion for CNS Disorders)

  2. Two new trials will give GLP-1 drugs to mostly healthy older adults to study brain aging (Medscape)

  3. More than 200 drugs in the GLP-1 and incretin class are now in development (The Manila Times)

  4. A woman who worked at a Boots pharmacy admitted taking Mounjaro from the store (Rhyl Journal)


Two men developed mood and psychotic symptoms after they stopped taking tirzepatide

Key Details:

  • Psychiatrists at the University of Pennsylvania described the two cases in a report published online October 22. Both men had a history of mental health conditions.

  • A 61-year-old man stopped the drug in August 2025 because of nausea. In October he was admitted with confusion, paranoia, and hallucinations he could hear and see.

  • A 52-year-old man stopped abruptly in September 2025 after losing 100 pounds over six months. He was later treated for manic symptoms, and his vitamin B12 level was low.

  • The authors wrote that stopping the drug "may contribute" to these symptoms in some at-risk patients, and that it "may represent an underrecognized clinical phenomenon."

Source: Primary Care Companion for CNS Disorders


Two new trials will give GLP-1 drugs to mostly healthy older adults to study brain aging

Key Details:

  • A trial from Vero Bioscience and the Atria Health and Research Institute is recruiting people aged 50 to 75 in stable health. The treatment group takes tirzepatide for six months, up to 10 milligrams a week, and the main measure is brain age from a protein test made by Vero co-founder Tony Wyss-Coray of Stanford. About 22 people are expected to take part.

  • A larger trial in Switzerland called PROMOTE, starting later this year, will include 180 people aged 50 to 70 who are generally healthy but have at least two risk factors, like borderline high blood pressure or prediabetes. It will compare the drug with a placebo for a year, and the drug has not been chosen yet.

  • No large drug company has said it wants to test GLP-1s in healthy people, so these trials come from startups and university groups.

  • Heike Bischoff-Ferrari of the University of Basel, one of the PROMOTE researchers, said "generally healthy" does not mean "without risk."

Source: Medscape


More than 200 drugs in the GLP-1 and incretin class are now in development

Key Details:

  • The firm counts over 180 companies working on them, with more than 30 in late-stage testing.

  • Besides obesity and type 2 diabetes, they are being tested for knee osteoarthritis pain, sleep apnea, and chronic low back pain.

  • In June, China's drug regulator accepted Hansoh's application for olatorepatide for chronic weight management.

Source: The Manila Times


A woman who worked at a Boots pharmacy admitted taking Mounjaro from the store

Key Details:

  • Justine Ettery, 55, pleaded guilty to theft by an employee at Llandudno Magistrates Court on Wednesday.

  • She took Mounjaro worth 3,492 pounds from the Prestatyn branch between April and July 2025.

  • She received an eight-month prison sentence, suspended for a year and a half.

  • No compensation was ordered because she had already paid the money back to Boots.

Source: Rhyl Journal


Learn More

Amanda Bonello

This is a reader-supported publication, thank you so much for your support.

💖

Instagram · TikTok · LinkedIn


Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured.

Discussion about this episode

User's avatar

Ready for more?